2010
DOI: 10.1182/blood.v116.21.4894.4894
|View full text |Cite
|
Sign up to set email alerts
|

Comparing the Outcomes of CHOP Chemotherapy Alone with Rituximab Plus CHOP for Hong Kong Chinese Patients with Diffuse Large B-Cell lymphoma

Abstract: 4894 Introduction Diffuse large B-cell lymphoma (DLBL) is the commonest type of lymphoma worldwide. The condition is the same in Hong Kong and it accounts for about 30–40% of lymphoma cases. CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) was used for treatment of DLBL for many years. Rituximab, a chimeric anti-CD20 monoclonal antibody was used for the treatment of DLBL for about 10 years. Previous studies have shown the better efficacy of … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles